Smith & Nephew, DFB deal

Smith & Nephew will acquire DFB's Healthpoint Biotherapeutics subsidiary for $782 million in cash. Smith &

Read the full 160 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE